Tranquis Therapeutics, Inc.

Aug. 29, 2022 12:00 UTC -TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD 2022, the 9th Aging Research and Drug Discovery meeting, taking place August 29 to September 2, 2022 at the University of Copenhagen, Denmark. In the preclinical study conducted in 18-month-old mice, it was shown that treatment for four months with TQS-168 resulted in a 66% improvement in the 31-point Frailty Index, a commonly used measurement to evaluate aging-related changes in mice. Treatment with TQS-168 also resulted in improvements in grip strength and treadmill running endurance, and a reduction in fat mass with no change in lean mass. These results indicate that TQS-168 has robust geroprotective effects in mice. TQS-168 was found to be well tolerated in healthy adult male subjects in a Phase 1 clinical trial. Adverse events were mild and transient, and no abnormalities were observed in laboratory parameters, ECG, or vital signs. No serious adverse events occurred. TQS-168 is ready for clinical trials to evaluate its potential to impact human aging and quality of life in the elderly. Tranquis is also advancing TQS-168 into clinical studies in other indications. About TQS-168 and PGC-1a TQS-168 is a PGC-1a-enhancing small molecule in development for the treatment of neurodegenerative, metabolic, and aging-related diseases in which PGC-1a modulation plays a critical role. PGC-1a is a transcriptional coactivator that regulates genes involved in cell energy metabolism, acting as a key regulator of mitochondrial biogenesis, giving TQS-168 potential as a target in a broad spectrum of diseases. TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease. TQS-168 also demonstrated compelling biomarker data, including increased PGC-1a gene expression, reduction of inflammatory monocytes and cytokines, and reduced levels of neurofilament light in animal models. In vitro, TQS-168 also shows specific immunomodulatory effects in myeloid cell lines and in white blood cells from people living with ALS. About Tranquis Tranquis is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of modulating PGC-1a to restore normal cell homeostasis and function. Tranquis’ platform has the potential to revolutionize the management of an entire range of indications in the fields of neurodegeneration, mitochondrial diseases, immuno-inflammation, and immunosenescence. In addition, the Company’s approach may promote healthy aging and longevity.

June 21, 2022 12:00 UTC -Tranquis plans to start a Phase 2 trial in people living with ALS by the end of 2022- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for TQS-168, a small molecule modulator of PGC-1a, for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a devastating disease with a high unmet need. Tranquis expects to begin a Phase 2 study of TQS-168 in people living with ALS by the end of 2022. The FDA’s Office of Orphan Drug Products grants orphan status to drugs and biologics that demonstrate promise for the treatment of diseases or conditions affecting fewer than 200,000 people in the United States. Orphan drug designation provides Tranquis with certain development incentives, including tax credits for qualified clinical trials, exemptions from FDA user fees, and the potential for seven years of market exclusivity, if TQS-168 is approved. “The orphan drug designation is an important regulatory milestone for Tranquis, further validating our efforts to develop TQS-168, an orally administered compound that targets PGC-1a in myeloid cells, as a novel therapeutic option for people living with ALS,” said Jonas Hannestad, MD, PhD, Chief Medical Officer at Tranquis. “Earlier this month, we reported Phase 1 data on TQS-168 in 78 healthy volunteers demonstrating excellent pharmacokinetic properties and blood plasma exposures associated with clinical benefit in preclinical models, along with a favorable safety and tolerability profile. We look forward to rapidly advancing our Phase 2 program in ALS.” About TQS-168 and PGC-1a TQS-168 is a PGC-1a-targeting small molecule in development for the treatment of ALS and other neurodegenerative diseases in which dysfunction of myeloid cells plays a critical role. PGC-1a is a transcriptional coactivator that regulates genes involved in cell energy metabolism, acting as a key regulator of mitochondrial biogenesis. When upregulated in dysfunctional myeloid cells, PGC-1a normalizes cell energy metabolism and immune function, giving it potential as a target in a variety of neurodegenerative diseases. TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease. TQS-168 also demonstrated compelling biomarker data, including increased PGC-1a gene expression, reduction of inflammatory monocytes and cytokines, and reduced levels of neurofilament light in animal models. In vitro, TQS-168 also shows specific immunomodulatory effects in myeloid cell lines and in white blood cells from people living with ALS. About Tranquis Tranquis is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. Tranquis’ therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a homeostatic functional state by targeting master regulators of cell energy metabolism, such as PGC-1a. Tranquis’ platform has the potential to revolutionize the management of an entire range of indications in the fields of neurodegeneration, mitochondrial diseases, immuno-inflammation, and immunosenescence. In addition, the Company’s approach may promote healthy aging and longevity.

-TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties- -Tranquis plans to start a Phase 2 trial in ALS by the end of 2022- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Tranquis Therapeutics Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Single and multiple doses of TQS-168 were well tolerated in 78 healthy volunteers, and no serious adverse events were reported. Adverse events were mild, transient, and did not lead to treatment discontinuation. TQS-168 also demonstrated excellent pharmacokinetic properties with adequate plasma exposures. Based on these results, Tranquis plans to initiate a Phase 2 clinical trial of TQS-168 in ALS by the end of the year. “The data from our Phase 1 study of TQS-168 demonstrate that target plasma exposures can be achieved at dose levels that are well tolerated. The ability to reach human exposures that were associated with benefits in preclinical models of ALS bolsters our confidence in Tranquis’ approach. We are developing an orally administered compound that targets PGC-1a in myeloid cells to treat neurodegenerative diseases in which dysfunctional myeloid cells play a key role in disease progression,” said Jonas Hannestad, MD, PhD, Chief Medical Officer at Tranquis. “By the end of the year, we plan to advance TQS-168 into a Phase 2 study in people living with ALS, a devastating disease with high unmet need.” Tranquis will use clinical evidence from its ALS program to inform the further development of TQS-168, and its second drug candidate, TQS-621, as well as next-generation compounds in a broad range of diseases that share the same underlying myeloid cell metabolic dysfunction. About TQS-168 and PGC-1a TQS-168 is a PGC-1a-targeting small molecule in development for the treatment of ALS and other neurodegenerative diseases in which dysfunction of myeloid cells plays a critical role. PGC-1a is a transcriptional coactivator that regulates genes involved in cell energy metabolism, acting as a key regulator of mitochondrial biogenesis. When upregulated in dysfunctional myeloid cells, PGC-1a normalizes cell energy metabolism and immune function, giving it potential as a target in a variety of neurodegenerative diseases. TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease. TQS-168 also demonstrated compelling biomarker data, including increased PGC-1a gene expression, reduction of inflammatory monocytes and cytokines, and reduced levels of neurofilament light. In vitro, TQS-168 also shows specific immunomodulatory effects in myeloid cell lines and in white blood cells from people living with ALS. About Tranquis Tranquis is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. Tranquis’ therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a homeostatic functional state by targeting master regulators of cell energy metabolism, such as PGC-1α. Tranquis’ platform has the potential to revolutionize the management of an entire range of indications in the fields of neurodegeneration, mitochondrial diseases, immuno-inflammation, and immunosenescence. In addition, the Company’s approach may promote healthy aging and longevity.